Brief: Hepion Pharma Data Safety Monitoring Board Recommends Continuation Of Phase 2a Ambition Clinical Trial For Treatment Of Advanced NASh
18/11/2020 13:39
Nov 18 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS DATA SAFETY MONITORING BOARD
RECOMMENDS
CONTINUATION OF PHASE 2A 'AMBITION' CLINICAL TRIAL FOR TREATMENT
OF ADVANCED NASH
* HEPION - INTERIM DSMB REVIEW AT MIDPOINT OF 1ST DOSE
COHORT
AFFIRMED NO SAFETY OR TOLERABILITY CONCERNS WITH 75MG OF CRV431
IN NASH PATIENTS
* HEPION PHARMACEUTICALS INC - STUDY WILL NOW ENROLL NASH
PATIENTS
IN THE 225 MG DOSE COHORT
Source text for Eikon: [ID:https://bit.ly/3lUz5nS]
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement